Delayed ischemic neurological deficit (DIND) is a major driver of adverse outcomes in
patients with aneurysmal subarachnoid hemorrhage (aSAH), defining an unmet need for …

Secondary brain injury after aneurysmal subarachnoid hemorrhage (SAH-SBI) contributes to
poor outcomes in patients after rupture of an intracranial aneurysm. The lack of diagnostic …

Sickle cell disease (SCD) is an inherited hemolytic anemia caused by a single point
mutation in the β-globin gene of hemoglobin that leads to synthesis of sickle hemoglobin …

After intracranial hemorrhage, heme is released from cell-free hemoglobin. This red blood
cell component may drive secondary brain injury at the hematoma‒brain interface. This …

Heme is an erythrocyte-derived toxin that drives disease progression in hemolytic anemias,
such as sickle cell disease. During hemolysis, specialized bone marrow-derived …

Microscopic hemorrhage is a common aspect of cancers, yet its potential role as an
independent factor influencing both cancer progression and therapeutic response is largely …

Background The functional neurological outcome of patients with intracerebral hemorrhage
(ICH) strongly relates to the degree of secondary brain injury (ICH-SBI) evolving within days …

Background Agonistic anti-CD40 monoclonal antibodies (mAbs) have emerged as
promising immunotherapeutic compounds with impressive antitumor effects in mouse …

Introduction Preclinical studies provided a strong rationale for a pathophysiological link
between cell-free hemoglobin in the cerebrospinal fluid (CSF-Hb) and secondary brain …

Cell-free hemoglobin (Hb) is a driver of disease progression in conditions with intravascular
or localized hemolysis. Genetic and acquired anemias or emergency medical conditions …